Cognition Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Cognition Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-87.8%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-87.8%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Sep 06

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease

Jul 31

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

May 22

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Apr 18

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Nov 30

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Aug 15

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Mar 17

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

Sep 27

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Aug 12

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

Aug 05

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Mar 19

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CGTX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CGTX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Cognition Therapeutics Piyasaya Karşı Temettü Getirisi

CGTX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CGTX)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (CGTX) (3 yıla kadar)	n/a

Önemli Temettü: CGTX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CGTX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CGTX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CGTX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Cognition Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Cognition Therapeutics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Cognition Therapeutics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Cognition Therapeutics, Inc. Publishes EEG Findings from Phase 2QUEL Study of CT1812 in Mild-to-Mod Moderate Alzheimer's Disease

Cognition Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease

Cognition Therapeutics, Inc’s Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

Cognition Therapeutics, Inc. Announces Results from Cognition Therapeutics' Phase 2 Shine Study of CT1812 in Mild-To-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

New major risk - Financial position

Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

Cognition Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Cognition Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Cognition Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $11.499999 million.

Cognition Therapeutics, Inc. Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-To-Mod Moderate Alzheimer's Disease

Cognition Therapeutics, Inc. Appoints Quang Pham as Board Director

Cognition Therapeutics, Inc. Appoints Quang Pham as Board Director

Cognition Therapeutics, Inc. Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease At CTAD

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 19% to US$6.25

Cognition Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Share price stability

Cognition Therapeutics, Inc. and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 Start Study in Early Alzheimer's Disease

Cognition Therapeutics, Inc. Announces Positive Topline Results for CT1812 Phase 2 Sequel Study for Mild-To-Moderate Alzheimer’s Disease

Cognition Therapeutics, Inc. Publishes Clinical Evidence that CT1812 Displaces Aß Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease

Price target decreased by 26% to US$7.75

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.7% to US$10.50

Cognition Therapeutics, Inc. Completes Enrollment of CT1812 Phase 2 Sequel Study for Mild-to-Moderate Alzheimer’s Disease

Cognition Therapeutics, Inc. Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease

Cognition Therapeutics, Inc Presents Scientific Rationale, Clinical Biomarker and Preclinical Data Supporting A Phase 2 Clinical Trial with Ct1812 in Geographic Atrophy Secondary to Dry AMD

Cognition Therapeutics, Inc. Highlights Phase 2 Shimmer Study of Ct1812 in Dementia with Lewy Bodies in Presentation At Ctad

Price target decreased to US$11.50

High number of new and inexperienced directors

Cognition Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6 million.

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support Sequel Clinical Trial

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Cognition Therapeutics, Inc. Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer's Disease Processes

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

Cognition Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Cognition Therapeutics, Inc. Announces CFO Changes

Cognition Therapeutics, Inc. Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

Cognition Therapeutics, Inc. to Report Q1, 2022 Results on May 11, 2022

High number of new and inexperienced directors

Cognition Therapeutics, Inc., Annual General Meeting, Jun 10, 2022

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

High number of new and inexperienced directors

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin